Revolution Medicines, Inc. files 10-Q

Revolution Medicines reported a net loss of $453.8 million for the first quarter of 2026, a significant increase from the prior year's $213.4 million net loss, driven by higher research and development expenses. The company also raised substantial capital through equity and debt offerings in April 2026.